Europe Approves First-in-World Drug for Aggressive Lung Cancer Based on Lurbinectedin-Immunotherapy Combination
The European Commission has approved the combination of Zepzelca (lurbinectedin) with atezolizumab for first-line maintenance therapy of extensive-stage small cell lung cancer. The approval is based on results from the Phase 3 IMforte trial, which showed a 46% reduction in the risk of disease progression or death compared with atezolizumab monotherapy.
European Breakthrough in Small Cell Lung Cancer Treatment: Analysis of the Lurbinectedin-Atezolizumab Combination Approval
The Gist: What's Really Happening
On May 31, 2026, the European Commission approved the combination of Zepzelca (lurbinectedin) with Tecentriq (atezolizumab) for first-line maintenance therapy of extensive-stage small cell lung cancer. Behind this dry formulation lies a fundamental shift in understanding how chemotherapy works in the era of immuno-oncology. This is not just about adding another drug to the regimen; it is the first randomized Phase 3 trial in nearly a decade to prove that adding a cytotoxic agent to immunotherapy can synergistically improve overall survival—not just delay progression.
The true meaning of this development lies in rethinking the role of "old school" chemotherapy. Mainstream medicine has long held the paradigm that immunotherapy "teaches" the immune system, while chemo is merely brute force that kills indiscriminately. The IMforte data show that lurbinectedin, as an RNA polymerase II inhibitor, works more subtly. It induces immunogenic cell death, which turns a "cold" tumor microenvironment into a "hot" one, making cancer cells visible to atezolizumab. This is not a combination—it is a convergence.
Furthermore, this approval shatters skepticism about the maintenance therapy strategy in aggressive tumors. Doctors have long feared that patients with ES-SCLC are so depleted by induction therapy with carboplatin and etoposide that they cannot tolerate additional chemo. Yet, the discontinuation rate due to toxicity in the combination arm was only 6.2% versus 3.3% in the atezolizumab-alone arm. This suggests that side-effect management protocols have reached a new level.
Timeline and Context
The path to this approval did not start today. The FDA (USA) was the first to greenlight this combination back in October 2025, making the US a pioneer in this regimen. However, the EMA is traditionally considered a more conservative regulator when it comes to combinations with high toxicity, so the European approval carries particular weight.
Key point: On March 27, 2026, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, which always serves as a predictor of final registration. Two months passed—the standard timeframe for bureaucratic procedures. On June 1, 2026, PharmaMar officially announced the registration. Simultaneously, Europe granted the drug orphan status, confirming that the disease is considered rare (fewer than 5 per 10,000 population). For Europe, this means 62,000 new cases per year—a huge number for orphan status, reflecting the severity of the prognosis.
What most analysts overlook: the publication date of the study in The Lancet (June 14, 2025) coincided with its presentation at ASCO 2025. Typically, there is a 1.5-2 year gap between publication of the "homework" and registration. Here, it was less than a year. This indicates that within the EMA and FDA, there was an unspoken priority (Fast Track) for this combination. Internal correspondence likely showed that agencies understood: without lurbinectedin, these patients die within months, and every week of delayed death matters.
Who Wins and Who Loses
Winners #1: PharmaMar and Jazz Pharmaceuticals. The financial model here is simple and brutal. PharmaMar already struck a deal with Jazz Pharmaceuticals for up to $1 billion for US rights. European approval opens the door for negotiations with EU distributors. Simply Wall St forecasts show that PharmaMar must grow revenue by 39.3% annually until 2028 (to €511.8 million). Without this approval, growth would have been impossible. Now investors will get their 31% upside from the current price.
Winners #2: Roche. Atezolizumab (Tecentriq) was losing exclusivity and therapeutic novelty in the face of competition from durvalumab (Imfinzi). The combination with lurbinectedin gives Roche the opportunity to sell its drug not as monotherapy, but as a mandatory component of a "package." This is a classic lock-in strategy, where abandoning atezolizumab means losing access to effective chemo.
Losers: Developers of Tarlatamab (bispecific T-cell engager). Amgen and other companies that invested in BiTE for SCLC have just gained a serious competitor in the first line. Tarlatamab currently works mainly in relapse. If the IMforte regimen delays relapse by 2.5-3 months (median OS 13.2 vs. 10.6), the window for "salvage" therapies narrows.
Non-obvious loser: Patients with brain metastases. The IMforte protocol excluded patients with CNS metastases. This is a large segment of SCLC patients (up to 30-40% at diagnosis). The EC approved the drug with this restriction. Now oncologists will be forced to lie in documentation or use the drug off-label. This discriminates against patients with neurometastases, although a post-hoc analysis of Roche data may show that the combination works in them as well (data not yet available).
What the Media Isn't Saying
The numbers they paid for. Most news feeds are full of headlines like "27% reduction in risk of death." Sounds amazing. But let's look at absolute numbers: median overall survival increased from 10.6 to 13.2 months. The gain is 2.6 months. This is significant, but it is not a cure. In real clinical practice, given the drug's cost (thousands of euros per infusion), the discussion of "cost per month of life" will be brutal. Moreover, the toxicity profile is serious: anemia rate 31.8%, neutropenia 12.8%, nausea 36.4%.
The "silent" competition with NCCN. The US NCCN 2026 guidelines have already included this combination as a "preferred regimen." But European ESMO recommendations are lagging behind. This creates a standard of care gap. Wealthy patients from Germany or France may demand treatment per US guidelines, paying out of pocket, while public insurance systems try to save on atezolizumab monotherapy. This will lead to lawsuits.
The real-world evidence (RWE) problem. The study had an ideal patient: PS 0-1, no brain metastases, response to induction. In real-world European practice, such patients are a minority. Most barely complete 4 cycles of induction. Doctors face a dilemma: start the combination in a borderline patient, risking toxicity, or deny them a chance. In an interview with Targeted Oncology, Carl Gay, MD, from MD Anderson honestly says: patients who "limp to the finish" after platinum are poor candidates. But in real clinics, therapy denials lead to conflicts.
Forecast: Next 30 Days and 90 Days
Next 30 days: The "formulary battle" begins. UK's NICE and Germany's G-BA will start pharmacoeconomic evaluations. PharmaMar will submit a dossier for inclusion in reference pricing. The probability that NICE rejects the combination due to high ICER (Incremental Cost-Effectiveness Ratio) is estimated by me at 40%. The British are traditionally frugal. Doctors will have to submit individual funding requests (IFRs), creating administrative chaos.
Next 90 days (by September 2026): Watch for updates to ESMO guidelines. They are published annually, but given this breakthrough, an extraordinary supplement (living guideline) is possible. However, the main event is the publication of subgroup data. I expect Jazz to present an analysis of patients with high LDH levels (a marker of poor prognosis). The main study had stratification by LDH, but data were not fully disclosed. If it turns out that patients with high LDH do not benefit, this will create a niche for biomarker-directed selection.
Long-term trend (12 months): Currently, lurbinectedin is a marine alkaloid. But biosimilar attacks on atezolizumab will begin in 2-3 years. To maintain control, PharmaMar must start trials of the combination with other PD-1 inhibitors (e.g., pembrolizumab or cemiplimab) to avoid dependence on Roche. If this does not happen, the company will fall into a single-partner trap.
— Editorial Team
